Protective effect of a vitamin E analog, phosphatidylchromanol, against oxidative hemolysis of human erythrocytes.
The protective effect of a vitamin E analog, phosphatidylchromanol [1,2-diacyl-sn-glycero-3-phospho-2'-(hydroxyethyl)-2',5',7',8'-tetrameth yl-6'-hydroxychroman; PCh], against oxidative hemolysis of human erythrocytes was examined and was compared with those of vitamin E (alpha-tocopherol) and 2,2,5,7,8-pentamethyl-6-chromanol (PMC). These three compounds at 50 microM protected the erythrocytes from hemolysis, when erythrocyte suspension (10%, vol/vol) was incubated with a water-soluble radical generator, 2,2'-azobis(2-amidinopropane)-dihydrochloride (75 mM). When erythrocyte suspension was oxidized after pretreatment with these compounds (50 microM) for 30 min followed by washing, PCh protected about 54% of erythrocytes from the hemolysis, while alpha-tocopherol protected only about 16% of the cells and PMC did not show any protective effect. During preincubation, alpha-tocopherol, PMC, and PCh were incorporated into the cells at the concentration of 12.6, 3.7, and 16.3 nmol/mg protein, respectively. Moreover, PCh was found in the ghost membrane fraction at a 20% higher level than alpha-tocopherol, and no PMC was detected in this fraction. These results indicate that phosphatidyl group in PCh acts as an excellent carrier of chromanol moiety into cells as well as an anchor within membranes more efficiently than phytyl group in alpha-tocopherol. PMC seems to be slightly anchored within membranes because of the lack of hydrophobic side chain. The excellent antihemolytic activity of PCh is likely to be caused by its accumulation within erythrocyte membranes.
Koga
T
T
Noda Institute for Scientific Research, Chiba, Japan. tkoga@mail.kikkoman.co.jp
Moro
K
K
Terao
J
J
D000578:Amidines / Q000633:toxicity; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D002084:Butylated Hydroxytoluene / Q000494:pharmacology; D002839:Chromans / Q000378:metabolism / Q000494:pharmacology*; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D005609:Free Radicals / Q000378:metabolism; D020404:Glycerophospholipids; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D016877:Oxidants / Q000633:toxicity; D010084:Oxidation-Reduction; D010712:Phosphatidic Acids / Q000378:metabolism / Q000494:pharmacology*; D011341:Probucol / Q000494:pharmacology; D014810:Vitamin E / Q000378:metabolism / Q000494:pharmacology
D000578:Amidines; D000975:Antioxidants; D002839:Chromans; D005609:Free Radicals; D020404:Glycerophospholipids; D016877:Oxidants; D010712:Phosphatidic Acids; C086691:phosphatidylchromanol; D014810:Vitamin E; D002084:Butylated Hydroxytoluene; C046728:2,2'-azobis(2-amidinopropane); C029141:2,2,5,7,8-pentamethyl-1-hydroxychroman; D011341:Probucol